Hims & Hers Health reported fourth-quarter results on Monday that beat analysts' expectations, but the stock sank in extended ...

Hims & Hers Health (HIMS) has seen its shares decline over 17% in the past week since the U.S. Food and Drug Administration (FDA) announced ...

Hims & Hers Health reported fourth-quarter results on Monday that beat analysts’ expectations, but the stock sank in extended ...

Online health and wellness company Hims & Hers reported fourth-quarter earnings that beat Wall Street analysts' expectations ...

Revenue excluding its GLP-1 offering increased 43% to $1.2 billion in 2024 from a year earlier, said Chief Financial Officer Yemi Okupe. Including sales of its weight-loss treatments, revenue surged ...

Hims & Hers Health beat fourth-quarter estimates and guided for better-than-expected revenue in the first quarter and 2025. The telehealth provider logged earnings of 11 cents a share on revenue of ...

Shares of Hims & Hers Health (HIMS) shares plunged in late trading Monday after the company reported falling margins as costs ...

The blistering rally in Hims & Hers Health Inc. that’s captivated meme-stock traders has ground to a halt, setting up a ...

On Friday, the Food and Drug Administration declared the semaglutide shortage over, sending Hims & Hers shares down 26%.

Shares of Hims & Hers Health (HIMS) sank in after-hours trading after the healthcare company reported earnings for its fourth ...

智通财经APP获悉，远程医疗公司Hims & Hers Health (HIMS.US)公布2024年第四季度业绩。数据显示，该公司Q4营收同比增长95%至4.81亿美元，好于市场预期的4.7亿美元;每股收益为11美分，也好于市场预期的10美分。

The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk‘s (NYSE:NVO) was ...